A study to evaluate intravenous TAK-341 in patients with Multiple System Atrophy (H-53081)

A randomized double-blind placebo-controlled phase 2 study to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous TAK-341 in patients with Multiple System Atrophy

This study is a multicenter, randomized, double-blind, placebo-controlled phase 2 study to assess the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of TAK-341 administered as multiple intravenous (IV) infusions every 4 weeks (Q4W) over 52 weeks in male and female subjects with possible or probable multiple system atrophy (MSA), aged at least 40 years.